A Rival to Aspirin for Colon Cancer Prevention: Weight-Loss Injections
In this article
A Rival to Aspirin in Colon Cancer Prevention: Do GLP-1 Weight-Loss Injections Prevent Cancer?
An Unexpected Protector
Colorectal cancer is among the commonest and deadliest cancers worldwide. For years, the best-known pharmacological preventive agent was Aspirin , although risks such as gastric bleeding limited its use.
Recently, drugs that transformed diabetes and obesity treatment, commonly called weight-loss injections, have attracted attention for another potential benefit: GLP-1 Receptor Agonists (semaglutide, liraglutide, etc.).
Presented at the ASCO Gastrointestinal Cancers Symposium 2026 (Abstract 18), a study involving over 280,000 patients found these drugs reduced colon cancer risk more than aspirin. This article examines the development linking metabolic treatment with cancer prevention.
Study Scope: A Large Analysis of 280,000 Patients
Dr. Colton Jones and colleagues at the University of Texas asked whether GLP-1 drugs could provide prevention comparable to aspirin. They compared two large groups:
- Group 1 (GLP-1 Users): 140,828 patients taking these drugs for diabetes or obesity.
- Group 2 (Aspirin Users): 140,828 regular aspirin users for cardiovascular health or other reasons.
*Groups were fully matched for age, sex and health status using propensity score matching.
Results: 26% Lower Risk Than Aspirin
After approximately 5-6 years of follow-up, GLP-1 drugs provided stronger protection than aspirin, considered the gold standard.
Colon Cancer Risk: Relative Reduction
Cancer incidence was 0.13% with GLP-1 drugs versus 0.176% with aspirin.
Which Drug Was Effective?
The Only Agent with Significant Protection
Not Statistically Significant*
*Other drugs may have lacked sufficient statistical power because of small patient numbers, rather than being ineffective.
How Might They Protect, and to Whom Does This Apply?
Beyond weight loss, GLP-1 drugs may prevent cancer through anti-inflammatory (inflammation-reducing) and antiproliferative (cell-division-slowing) effects in intestinal cells.
Most participants were White women, whereas colorectal cancer risk is higher in Black men. Studies in more diverse groups are needed before generalizing to everyone.
- Jones C, et al. GLP-1 Receptor Agonists Show Potential Relative Reduction in CRC Incidence Compared With Aspirin. ASCO Gastrointestinal Cancers Symposium. 2026; Abstract 18.
- Lin A, et al. Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine. Biomark Res. 2025;13:50.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.